Jun 5, 2025 Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules Learn More
Jun 4, 2025 Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) Learn More
May 13, 2025 Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update Learn More
May 7, 2025 Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 Learn More